About NDA


Translational Science

NDA Advisory Board

Regulatory Affairs


High-Stakes Meetings

Health Technology Assessment


Meet the NDA Group at DIA in San Diego 23-27 June

14th June 2019

We will be attending DIA in San Diege 23-27 June. If you are planning to be there, we would really like to meet up with you!


Navigating the Regulatory Maze – Initiating Your Phase 1 Trials

4th June 2019

Welcome to NDA’s seminar on 2 July 12:00-14:00 in Cambridge, UK, on Navigating the Regulatory Maze – Initiating Your Phase 1 Trials.


Solve your most difficult regulatory challenge at BIO Philadelphia

27th May 2019

The path to approval is littered with pitfalls leading to unnecessary delays getting your medicine to the people who need it the most….the patients. Meet Dr Laurie Smaldone Alsup for a talk about how to resolve the issues.


Why should you engage early with regulators and HTA bodies?

14th May 2019

NDA’s Dr Mira Pavlovic-Ganascia and Claes Buxfeldt provide insight on what the expected outcomes of constructively engaging with regulators and HTA bodies could be.


The state of the Swedish orphan pipeline

7th May 2019

Business Sweden, together with SwedenBIO, have outlined the current state of Swedish orphan development in a new report. It describes a vibrant drug development landscape that is reflective of the global move towards orphan development and the strong emphasis on oncology.


Optimizing Value – Regulatory and Market Access Considerations

Welcome to NDA’s seminar on 21st May 08:30-13:00 in Solna, Sweden on Optimizing Value – Regulatory and Market Access Considerations.


4 ways that HTA will change under the new European regulation

6th May 2019

In this white paper NDA’s CEO, Johan Strömquist, discusses four ways that Health Technology Assessments will change under the new proposed European regulation.

More News
We have helped over 2,000 clients achieve success in the past
We have helped over 2,000 clients achieve success in the past

The leader in FDA Advisory Committee meeting preparation

“For innovative life science companies, NDA and PharmApprove are the best partners to help prepare to win at FDA Advisory Committees. Our pioneering approach — refined over 16 years experience and 150-plus projects — has helped more than 80 clients achieve success at these high-profile, high-stakes hearings.

NDA Intelligence

Subscribe to the latest intelligence from the true thought leaders in the field and access it at any time.


A Career with NDA

Join NDA and get the chance to work with some of the leading minds in regulatory affairs, pharmacovigilance, health technology assessment and scientific communications on a variety of projects, clients and geographies.

Why work at NDA?

Our Locations

NDA Sweden

NDA Group AB
Johanneslundsv. 2
S-194 61 Upplands Väsby

T. +46 (0)8 590 778 00
E. stockholm@ndareg.com

NDA France

7, rue Jobbé Duval,
75015 Paris,

T. +33 983 981 942
E. paris@ndareg.com

NDA Germany

Neumarkter Straße 18
D-81673 München

T. +49 (0)89 3585 4000
E. munich@ndareg.com

NDA Switzerland

Rigistrasse 5
8703 Erlenbach

T. +41 (0)78 951 9929
E. zurich@ndareg.com


Grove House
Guildford Road
Surrey KT22 9DF
United Kingdom

T. +44 (0) 1372 860 610
E. london@ndareg.com

NDA USA Massachusetts

NDA Regulatory Development Inc.
1 Broadway, 14th floor
Cambridge, MA 02142
United States

T. +1 609 583 1990
E. usa@ndareg.com

NDA USA New Jersey

200 Princeton South Corporate Center,
Suite 340
Ewing, NJ 08628
United States

T. +1 609 583 1990
E. usa@ndareg.com